Insulet (PODD +6.2%) finishes strong despite posting a mixed Q3 report yesterday. Revenue grew...

|About: Insulet Corporation (PODD)|By:, SA News Editor

Insulet (PODD +6.2%) finishes strong despite posting a mixed Q3 report yesterday. Revenue grew by 22% Y/Y, and investors are focusing on it's pipeline, which includes its OmniPod insulin pump currently awaiting FDA approval. Barrington thinks approval should come within 90 days. The firm expects the stock to outperform its peers once it's granted and reiterates an Outperform rating on the stock.